Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 15,249.70 -57.46 -0.38%
S&P 500 1,644.98 -10.37 -0.63%
Nasdaq 3,453.78 -9.52 -0.27%
Ticker Volume Price Price Delta
STOXX 50 2,771.72 -63.29 -2.23%
FTSE 100 6,684.45 -155.82 -2.28%
DAX 8,323.65 -207.24 -2.43%
Ticker Volume Price Price Delta
Nikkei 14,484.00 -1,143.28 -7.32%
Hang Seng 22,669.70 -591.40 -2.54%
S&P/ASX 200 5,062.45 -102.92 -1.99%
  • Exchange: -
  • Sector: Consumer, Non-cyclical
  • Industry: Biotechnology
  • Sub-Industry: Medical-Biomedical/Gene

ARYx Therapeutics Inc

4AX:GR

Ticker Delisted

Snapshot for ARYx Therapeutics Inc (4AX)

Open: - Day's Range: - Volume: 0
Previous Close: - 52wk Range: 0.001 - 0.015 1-Yr Rtn: -

Stock Chart for 4AX

No chart data available.
  • 4AX:GR 0.000
  • 1M
  • 1Y
0.000
Interactive 4AX Chart

Previous Close

Key Statistics for 4AX

Current P/E Ratio (ttm) -
Estimated P/E(12/2010) -
Relative P/E vs. DAX -
Earnings Per Share (ttm) -
Est. EPS (12/2010) -
Est. PEG Ratio -
Market Cap (M EUR) 0.00
Shares Outstanding (M) 0.00
30 Day Average Volume 0
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Last Dividend
5 Year Dividend Growth -
Next Earnings Announcement -
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for 4AX

No data available

Company Profile & Key Executives for 4AX

ARYx Therapeutics, Inc. researches and produces anticoagulants, and drugs for treating gastrointestinal disorders and atrial fibrillation.

Pascal DruzgalaSenior VP/Chf Scientific OfcrDaniel M CanafaxVP/Chief Development Officer
David NaglerVP:Corporate Affairs/Secretary
More Company Profile & Key Executives for 4AX

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Financial Commentaries

Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil